[Temporal arteritis: treatment controversies].
BACKGROUND
Although giant cell or temporal arteritis represents 5-10% of ischaemic optic neuropathies and is the most common arteritis in people over 60 years old. Currently there is no established treatment with oral glucocorticoids available.


BACKGROUND
Glucocorticoid (GC) is still the treatment of choice but has to be started without delay in order to prevent neurological or systemic complications. However, we can resort to intravenous treatment in cases where there is loss of sight or other neurological symptoms. In cases refractory to GC or in those in whom we wish to decrease the dose due to adverse effects, individualised treatment with methotrexate or TNF blockers could be indicated. There is insufficient evidence to recommend other treatments, such as azathioprine, dapsone, cyclosporine, cyclophosphamide or imitinib. In patients with vascular risk factors, anti-platelet therapy with ASA should be assessed. Surgical treatment should be considered in selected cases with symptoms due to arterial stenosis.


CONCLUSIONS
The corticoids continue to be the treatment of choice in temporal arteritis, however, given the clinical variability of the disease and the special characteristics of this group of patients, usually elderly and with systemic diseases, we believe that individualised treatment with coherent therapeutic guidelines are essential. Currently there is not only treatment with oral glucocorticoids available, although in our patients we can choose to use intravenous mega-doses, anti-platelet treatment, resort to methotrexate or TNF inhibitors in refractory cases, or even consider surgical approaches.
Balsalobre Aznar
J
J
Servicio de Reumatología, Grupo Hospiten, Tenerife, Santa Cruz, España. balsalobre@@yahoo.es
Porta-Etessam
J
J
D001241:Aspirin / Q000627:therapeutic use; D001549:Benzamides; D013700:Giant Cell Arteritis / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D000068877:Imatinib Mesylate; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D018917:Optic Neuropathy, Ischemic / Q000188:drug therapy* / Q000209:etiology / Q000601:surgery; D010879:Piperazines / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use
D001549:Benzamides; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D001241:Aspirin; D008727:Methotrexate